Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in ugandan adults

AIDS Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Lamorde, Mohammed ^a,b   Byakika Kibwika, Pauline ^a,b,c   Tamale, William S ^d   Kiweewa, Francis ^d   Ryan, Mairin ^b   Amara, Alieu ^e   Tjia, John ^e   Back, David ^e   Khoo, Saye ^e   Boffito, Marta ^f   Kityo, Cissy ^d   Merry, Concepta ^a,b,c  

^a MAKERERE UNIVERSITY   (Uganda)

^b ST JAMES S HOSPITAL   (Ireland)

^c Infectious Diseases Network for Treatment and Research in Africa   (Uganda)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873844577     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2012/105980     Document Type: Article

References (19)

1. FDA, Guidance for industry. Food-Effect Bioavailability and Fed Bioequivalence Studies 2002 Rockville, Md, USA Center for Drug Evaluation and Research, Food and Drug Administration
2. DHHS, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents, 2009
3. WHO, Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach 2010 Geneva, Switzerland WHO
4. MOH, National Antiretroviral Treatment Guidelines for Adults, Adolescents and Children 2009 3rd Uganda, Kampala Ministry of Health
5. Mathias A., Hinkle J., Menning M., Hui J., Kaul S., Kearney B. P., Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. Journal of Acquired Immune Deficiency Syndromes 2007 46 2 167 173 2-s2.0-34748832865 10.1097/QAI.0b013e3181427835 (Pubitemid 47482611)
6. ®Summary of Product Characteristics 2010 Cambridge, UK Gilead Sciences International
7. ®(efavirenz) Capsules and Tablets. Full Prescribing Information 2010 Princeton, NJ, USA Bristol-Myers Squibb Company
8. ®(emtricitabine/ tenofovir disoproxil fumarate) tablets. Full prescribing information. Gilead Sciences. http://www.truvada.com/ pdf/fpi.pdf, 2009
9. ®(efavirenz/emtricitabine/tenofovir disoproxil fumarate). Gilead Sciences and Bristol Myers Squibb, LLC. http://www.gilead.com/ pdf/atripla-pi.pdf, 2010
10. Weiser S. D., Tuller D. M., Frongillo E. A., Senkungu J., Mukiibi N., Bangsberg D. R., Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS ONE 2010 5 4 2-s2.0-77956402871 10.1371/journal.pone.0010340 e10340
11. Marzolini C., Telenti A., Decosterd L. A., Greub G., Biollaz J., Buclin T., Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001 15 1 71 75 2-s2.0-0035808574 10.1097/00002030-200101050-00011 (Pubitemid 32055781)
12. Clifford D. B., Evans S., Yang Y., Acosta E. P., Goodkin K., Tashima K., Simpson D., Dorfman D., Ribaudo H., Gulick R. M., Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Annals of Internal Medicine 2005 143 10 714 721 2-s2.0-28144452516
13. Haas D. W., Ribaudo H. J., Kim R. B., Tierney C., Wilkinson G. R., Gulick R. M., Clifford D. B., Hulgan T., Marzolini C., Acosta E. P., Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004 18 18 2391 2400 2-s2.0-19944428456 (Pubitemid 40065906)
14. Ribaudo H. J., Liu H., Schwab M., Schaeffeler E., Eichelbaum M., Motsinger-Reif A. A., Ritchie M. D., Zanger U. M., Acosta E. P., Morse G. D., Gulick R. M., Robbins G. K., Clifford D., Haas D. W., Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study. Journal of Infectious Diseases 2010 202 5 717 722 2-s2.0-77955685573 10.1086/655470
15. Barry M., Mulcahy F., Merry C., Gibbons S., Back D., Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clinical Pharmacokinetics 1999 36 4 289 304 2-s2.0-0032955402 10.2165/00003088-199936040-00004 (Pubitemid 29201737)
16. McCabe B. J., Frankel E. H., Wolfe J. J., Handbook of Food-Drug Interactions 2003 Boca Raton, Fla, USA CRC Press, LLC
17. Naesens L., Bischofberger N., Augustijns P., Annaert P., Van Den Mooter G., Arimilli M. N., Kim C. U., De Clercq E., Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2- phosphonylmethoxypropyl)adenine in mice. Antimicrobial Agents and Chemotherapy 1998 42 7 1568 1573 2-s2.0-0031863214 (Pubitemid 28311542)
18. Kearney B. P., Flaherty J. F., Shah J., Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical Pharmacokinetics 2004 43 9 595 612 2-s2.0-3242694930 10.2165/00003088-200443090-00003 (Pubitemid 38951802)
19. ®(emtricitabine) capsule, Emtriva (emtricitabine) oral solution. Full prescribing information. Gilead Sciences, 2011